1834 Investment Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.92M Buy
163,607
+3,065
+2% +$179K 1.24% 23
2025
Q4
$8.66M Buy
160,542
+970
+0.6% +$46.7K 1.09% 24
2025
Q3
$7.2M Buy
159,572
+2,075
+1% +$96.9K 0.88% 31
2025
Q2
$7.29M Sell
157,497
-1,293
-0.8% -$63.5K 0.92% 32
2025
Q1
$9.68M Sell
158,790
-4,603
-3% -$268K 1.25% 18
2024
Q4
$9.24M Sell
163,393
-10,518
-6% -$588K 1.17% 18
2024
Q3
$9M Sell
173,911
-1,522
-0.9% -$71.4K 1.05% 22
2024
Q2
$7.29M Buy
175,433
+5,543
+3% +$248K 0.88% 31
2024
Q1
$9.21M Buy
169,890
+34,336
+25% +$1.75M 1.09% 20
2023
Q4
$6.96M Sell
135,554
-6,682
-5% -$351K 0.83% 36
2023
Q3
$8.26M Sell
142,236
-71
-0% -$4.35K 1.03% 25
2023
Q2
$9.1M Buy
142,307
+28,843
+25% +$1.93M 1.08% 23
2023
Q1
$7.86M Buy
113,464
+5,346
+5% +$377K 0.94% 29
2022
Q4
$7.78M Sell
108,118
-4,218
-4% -$318K 1.11% 28
2022
Q3
$7.99M Sell
112,336
-701
-0.6% -$50.9K 1.2% 24
2022
Q2
$8.7M Sell
113,037
-67,853
-38% -$5.17M 1.23% 25
2022
Q1
$13.2M Sell
180,890
-33,636
-16% -$2.26M 1.62% 14
2021
Q4
$13.4M Buy
214,526
+2,175
+1% +$128K 1.51% 17
2021
Q3
$12.6M Buy
212,351
+4,950
+2% +$326K 1.53% 14
2021
Q2
$13.9M Buy
207,401
+5,428
+3% +$354K 1.68% 11
2021
Q1
$12.8M Sell
201,973
-5,972
-3% -$372K 1.65% 12
2020
Q4
$12.9M Buy
207,945
+5,653
+3% +$348K 1.72% 11
2020
Q3
$12.2M Buy
202,292
+13,998
+7% +$842K 1.78% 12
2020
Q2
$11.1M Buy
188,294
+71,746
+62% +$4.29M 1.75% 12
2020
Q1
$6.5M Sell
116,548
-56,034
-32% -$3.42M 1.23% 26
2019
Q4
$11.1M Sell
172,582
-20,723
-11% -$1.19M 1.7% 14
2019
Q3
$9.8M Buy
193,305
+176,297
+1,037% +$8.29M 1.42% 18
2019
Q2
$771K Buy
17,008
+1,411
+9% +$65.7K 0.12% 97
2019
Q1
$744K Sell
15,597
-1,489
-9% -$74.2K 0.11% 103
2018
Q4
$888K Sell
17,086
-1,966
-10% -$106K 0.15% 95
2018
Q3
$1.18M Sell
19,052
-695
-4% -$41.2K 0.17% 88
2018
Q2
$1.09M Sell
19,747
-131,601
-87% -$7.11M 0.17% 92
2018
Q1
$9.57M Buy
151,348
+1,963
+1% +$126K 1.64% 14
2017
Q4
$9.15M Buy
149,385
+10,652
+8% +$666K 1.44% 17
2017
Q3
$8.84M Buy
138,733
+968
+0.7% +$56.5K 1.65% 15
2017
Q2
$7.68M Buy
137,765
+5,699
+4% +$310K 1.45% 18
2017
Q1
$7.18M Sell
132,066
-1,878
-1% -$103K 1.38% 21
2016
Q4
$7.83M Buy
133,944
+20,860
+18% +$1.14M 1.58% 18
2016
Q3
$6.1M Buy
113,084
+30,066
+36% +$1.93M 1.32% 29
2016
Q2
$6.11M Sell
83,018
-59
-0.1% -$4.17K 1.33% 26
2016
Q1
$5.31M Buy
83,077
+7,095
+9% +$447K 1.21% 28
2015
Q4
$5.23M Buy
75,982
+5,251
+7% +$347K 1.23% 28
2015
Q3
$4.19M Buy
70,731
+30,115
+74% +$1.91M 1.04% 31
2015
Q2
$2.7M Buy
40,616
+25,561
+170% +$1.68M 0.74% 43
2015
Q1
$971K Hold
15,055
0.26% 84
2014
Q4
$889K Buy
15,055
+88
+0.6% +$4.96K 0.25% 87
2014
Q3
$766K Buy
14,967
+44
+0.3% +$2.2K 0.21% 91
2014
Q2
$724K Buy
14,923
+78
+0.5% +$3.84K 0.2% 96
2014
Q1
$771K Sell
14,845
-1,490
-9% -$79.3K 0.23% 89
2013
Q4
$868K Hold
16,335
0.25% 87
2013
Q3
$756K Sell
16,335
-819
-5% -$36K 0.25% 81
2013
Q2
$767K Buy
+17,154
New +$745K 0.26% 80

Other funds holding BMY

1834 Investment Advisors's BMY Position: Q1 2026 in Review

1834 Investment Advisors increased its Bristol-Myers Squibb (BMY) stake by 1.9% in Q1 2026, buying an estimated $179K and bringing the position to 163,607 shares worth $9.92M. The position accounts for 1.24% of the portfolio, ranked #23.

1834 Investment Advisors first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $13.9M in Q2 2021. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • 1834 Investment Advisors held 163,607 shares of Bristol-Myers Squibb worth $9.92M as of Q1 2026.
  • 1834 Investment Advisors bought 3,065 Bristol-Myers Squibb shares in Q1 2026, an estimated $179K.
  • Bristol-Myers Squibb made up 1.24% of 1834 Investment Advisors's portfolio in Q1 2026, its #23 holding.
  • 1834 Investment Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • 1834 Investment Advisors's Bristol-Myers Squibb position peaked at $13.9M in Q2 2021.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on 1834 Investment Advisors's 13F filing for Q1 2026, filed 14 May 2026.